#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“What we’re seeing in the lab with cannabinoid reversal of neuroinflammation is genuinely encouraging, but we need to be careful not to confuse mechanistic promise with clinical readiness. I tell my patients with neuroinflammatory concerns that we have early signals worth monitoring, not yet evidence that justifies changing their treatment, and that distinction matters for responsible prescribing.”
💊 While preclinical findings on cannabis compounds reversing metabolic dysfunction-associated fatty liver disease (MAFLD) are intriguing, clinicians should recognize that laboratory evidence in animal models or cellular systems often does not translate reliably to human clinical benefit, and the current evidence base remains insufficient to recommend cannabis or its derivatives for MAFLD management. The heterogeneity of cannabis compounds, variable bioavailability, potential drug interactions, and the lack of standardized dosing regimens further complicate the translation from bench to bedside. Moreover, MAFLD is multifactorial, involving diet, exercise, metabolic disorders, and genetics, which means that even if a single compound showed efficacy in controlled studies, it would likely represent only one component of a comprehensive treatment strategy. Until well-designed randomized controlled trials in humans establish safety and efficacy with appropriate comparator arms, clinicians should continue counseling patients on proven intervent
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: